Curacao vs Kazakhstan: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Curacao
0.2%
in 2024
Kazakhstan
0.2%
in 2024
Curacao rank
99th
Kazakhstan rank
99th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Curacao
- Kazakhstan
How they compare
Curacao currently reports 0.2% against 0.2% in Kazakhstan, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Curacao ahead.
Curacao ranks 99th and Kazakhstan ranks 99th of 247 countries.
Curacao has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Curacao | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.2% | 0.1% | Curacao |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Curacao or Kazakhstan?
- Curacao, at 0.2% against 0.2% in Kazakhstan as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Curacao and Kazakhstan?
- 0.0%, with Curacao ahead.
- How many years of comparable data are there for Curacao and Kazakhstan?
- 10 years are reported by both, from 2015 to 2024.
- How do Curacao and Kazakhstan rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Curacao ranks 99th and Kazakhstan ranks 99th of 247 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.